| 货号 | MAB10741-SP |
| 别名 | C21orf43; CD322 antigen; CD322; JAM2; JAMB; JAM-BJAM-IT/VE-JAM; junctional adhesion molecule 2JAM-2; junctional adhesion molecule B; PRO245; Vascular endothelial junction-associated molecule; VE-JAM; VE-JAMVEJAMCD322 | 全称 | Junctional Adhesion Molecule B |
| 反应种属 | Human |
| 应用 | Western Blot,Neutralization |
| 目标/特异性 | Detects human JAM‑B/VE-JAM in direct ELISAs and Western blots. |
| 使用方法 | Western Blot: 1 µg/mL Neutralization: Measured by its ability to neutralize JAM‑B/VE‑JAM-mediated adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line. Fong, S. et al. (2002) J. Immunol. 168:1618. The Neutralization Dose (ND50) is typically 0.6-3.0 µg/mL in the presence of 0.2 µg/mL Recombinant Human JAM‑B/VE‑JAM Fc Chimera. |
| 来源 | Monoclonal Mouse IgG2B Clone # 156624 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 58494 (Human); 67374 (Mouse) |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human JAM‑B/VE-JAM Phe29-Asn236 (predicted) Accession # P57087 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | The family of juctional adhesion molecules (JAM), comprising at least three members, are type I transmembrane receptors belonging to the immunoglobulin (Ig) superfamily (1, 2). These proteins are localized in the tight junctions between endothelial cells or epithelial cells. Some family members are also found on blood leukocytes and platelets. JAM-B, alternatively named vascular endothelial JAM (VE-JAM), is expressed prominently on high endothelial venules of lymphoid organs where it is localized to the intercellular boundaries of high endothelial cells. It is also expressed on the endothelium of a variety of non-lymphoid organs, especially the heart and placenta (3, 5). Human JAM-B cDNA predicts a 298 amino acid (aa) precursor protein with a putative 28 aa signal peptide, a 209 aa extracellular region containing two Ig domains, a 23 aa transmembrane domain and a 38 aa cytoplasmic domain containing a PDZ-binding motif and a PKC phosphorylation site. Human JAM-B shares approximately 79% aa sequence homology with its mouse homologue. It also shares approximately 35% aa sequence homology with human JAM-A or JAM-C. JAM-B exhibits homotypic interactions, as well as heterotypic interactions with JAM-C, but not JAM-A (4, 5, 7). It is also a ligand for the Integrin alpha 4beta1. However, the JAM-B/ alpha 4beta1 interaction is facilitated only after prior adhesion of JAM-B to JAM-C (6). Through its heterotypic interactions with JAM-C, JAM-B is an adhesive ligand for T, NK, and dendritic cells, and may play a role in regulating leukocyte transmigration (5). The nomenclature used for the JAM family proteins is confusing. VE-JAM has been referred in the literature variously as JAM-B or JAM-3. Until further clarification, R&D Systems has adopted the nomenclature where both mouse and human VE-JAM are referred to as JAM-B. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
Cell Adhesion Mediated by JAM‑B/VE‑JAM and Neutralization by Human JAM‑B/ VE‑JAM Antibody. Recombinant Human JAM‑B/VE‑JAM Fc Chimera (Catalog # 1074-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Human JAM‑B/VE‑JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human JAM-B/ VE-JAM Monoclonal Antibody (Catalog # MAB10741). The ND50 is typically 0.6-3.0 µg/mL. |
